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Abstract
Genome-wide association studies (GWAS) of colorectal cancer (CRC) have been conducted
primarily in European descendants. In a GWAS conducted in East Asians, we first analyzed
approximately 1.7 million single-nucleotide polymorphisms (SNPs) in four studies with 1,773
CRC cases and 2,642 controls. We then selected 66 promising SNPs for replication and genotyped
them in three independent studies with 3,612 cases and 3,523 controls. Five SNPs were further
evaluated using data from four additional studies including up to 3,290 cases and 4,339 controls.
SNP rs7229639 in the SMAD7 gene was found to be associated with CRC risk with an odds ratio
(95% confidence interval) associated with the minor allele (A) of 1.22 (1.15-1.29) in the combined
analysis of all 11 studies (P = 2.93×10−11). SNP rs7229639 is 2,487 bp upstream from rs4939827,
a risk variant identified previously in a European-ancestry GWAS in relation to CRC risk.
However, these two SNPs are not correlated in East Asians (r2 = 0.008) nor in Europeans (r2 =
0.146). The CRC association with rs7229639 remained statistically significant after adjusting for
rs4939827 as well as three additional CRC risk variants (rs58920878, rs12953717, and rs4464148)
reported previously in this region. SNPs rs7229639 and rs4939827 explained approximately 1% of
the familial relative risk of CRC in East Asians. This study identifies a new CRC risk variant in
the SMAD7 gene, further highlighting the significant role of this gene in the etiology of CRC.
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Introduction
Colorectal cancer (CRC) is the third-most common cancer and second-leading cause of
cancer death worldwide (1). While environmental factors are believed to play an important
role in the etiology of CRC, it is estimated that approximately 35% of CRC risk may be
attributable to inherited factors (2). To date, approximately 19 common genetic
susceptibility loci for CRC have been identified in genome-wide association studies
(GWAS) (3-13). However, these genetic variants, along with high-penetrance germline
mutations in known CRC susceptibility genes, including APC, the DNA mismatch repair
genes, SMAD4, AXIN2, BMPR1A, TGFBR2, POLD1, STK11, and MUTYH (14;15), explain
less than 15% of excess familial risk of CRC (3-15).
Most previous GWAS for CRC were conducted in European-ancestry populations. Given
the potential difference in genetic architectures between East Asians and European ancestry
populations, it is possible that some genetic risk variants for CRC identified in European
descendants may not be generalizable to East Asians. Also, GWAS conducted in East
Asians could possibly identify genetic risk variants unique to this population. In 2009, we
Zhang et al. Page 2
Int J Cancer. Author manuscript; available in PMC 2015 August 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
initiated a GWAS in East Asians, the Asia Colorectal Cancer Consortium, and identified
three novel genetic susceptibility loci for CRC (16). In this paper, we reported additional
findings from this consortium regarding the identification of a new risk variant for CRC in
the SMAD7 gene.
Materials and Methods
Study populations
This study, conducted as part of the Asia Colorectal Cancer Consortium, included 8,891
CRC cases and 10,547 cancer-free controls of East Asian ancestry recruited in eight centers
located in China, Korea, Japan, and Singapore (Table 1). Specifically, Stage 1 consisted of
four studies: Shanghai Study 1 (Shanghai-1, n = 982), Shanghai Study 2 (Shanghai-2, n =
553), Guangzhou Study 1 (Guangzhou-1, n = 1,666), Aichi Study 1 (Aichi-1, n = 1,439).
Stage 2 consisted of seven studies: Guangzhou Study 2 (Guangzhou-2, n = 2,892), Korean-
National Cancer Center Study (Korea-NCC, n = 2,721), Seoul Study (Korea-Seoul, n =
1,522), Korean Cancer Prevention Study-II (KCPS-II, n = 1,302), the Japan-BioBank Study
(Japan-BioBank, n = 3,498), Singapore Chinese Study (SCH, n = 2,000), and Aichi Study 2
(Aichi-2, n = 863). Summary descriptions of these 11 participating studies from eight
centers are provided in Supplementary Methods. Study protocols were approved by
relevant institutional review boards for all study sites.
Laboratory procedures
Genomic DNA was extracted from either blood or saliva samples according to standard
protocols. In Stage 1, genotyping was performed using Affymetrix Genome-Wide Human
SNP Array 6.0 (Affy 6.0, 906,602 SNPs) for Shanghai-1 cases and controls; Illumina
HumanOmniExpress BeadChip (Illumina OmniExpress, 729,462 SNPs) for Shanghai-2
cases and controls, Guangzhou-1 cases and Aichi-1 cases; Illumina Human610-Quad
BeadChip (620,901 SNPs) for Guangzhou-1 controls; and Illumina Infinium HumanHap610
BeadChip (592,044 SNPs) for Aichi-1 controls. Genotype calling was performed using
Birdseed algorithm for Affymetrix 6.0 or GenomeStudio software for Illumina GWAS
platforms based on manufacturer's protocols.
Quality control (QC) protocols were applied to exclude samples and SNPs from all four
studies in Stage 1 as described previously (17-19), including: 1) genotype call rate per
sample < 95%, 2) genetically identical (PI_HAT > 0.9) or duplicated samples, 3) genetic sex
inconsistent with survey/clinical data, 4) samples with close relative (PI_HAT > 0.25), 5)
population structure inconsistent with HapMap Asians (see Statistical analysis), 6)
genotype call rate per SNP < 95%, 7) minor allele frequency (MAF) < 0.05, 8) genotyping
concordance < 95% in QC samples, 9) Hardy-Weinberg equilibrium (HWE) P < 1×10−5 in
controls, or 10) SNPs not in autosomes. After these QC procedures, 580,086 SNPs for 971
individuals (474 cases and 497 controls) remained in the Shanghai-1 dataset; 515,701 SNPs
for 485 individuals (254 cases and 231 controls) remained in the Shanghai-2 dataset;
522,096 SNPs for 641 cases and 435,925 SNPs for 972 controls remained in the
Guangzhou-1 dataset; and 478,246 SNPs for cases and 443,065 SNPs for controls remained
in the Aichi-1 dataset.
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Stage 2 genotyping was performed using the Sequenom MassARRAY platform (Sequenom,
San Diego, CA, USA) for the promising 66 SNPs selected from Stage 1. These SNPs were
genotyped in Guangzhou-2, Korea-NCC, and Korea-Seoul studies. Again in Stage 2,
standard QC protocols were applied to exclude SNPs, including: 1) genotype call rate per
SNP < 95%, 2) unclear genotyping cluster, 3) genotyping concordance < 95% in QC
samples, 4) HWE P < 7.7×10−4 (0.05/65) in controls. After these QC procedures, the
number of eligible SNPs was 65 in Guangzhou-2, 64 in Korea-NCC, and 60 in Korea-Seoul
studies. Five of these SNPs were taken forward for in silico replication in KCPS-II (n = 5),
Japan-BioBank (n = 5), and SCH (n = 2; rs7229639 and rs2143619). Genotyping was
conducted using either Affymetrix Genome-Wide Human SNP Array 5.0 in KCPS-II or
Illumina HumanHap 610K and 550K in Japan-BioBank or Affymetrix Genome-Wide
Human SNP Array 6.0 for SCH. Details of the QC procedures and data processing for
samples included in these three studies have been previously reported in elsewhere
(11;20;21). Finally, SNP rs7229639 was further genotyped in Aichi-2 using Sequenom
along with SNPs for other projects.
Statistical analysis
Genome-wide imputation for samples in four Stage 1 studies was performed using program
MACH 1.0 (22) based on data from the 90 CHB (Han Chinese in Beijing, China) and JPT
(Japanese in Tokyo, Japan) samples included in the HapMap project (release 22). After
exclusion of imputed SNPs with MAF < 0.05 and RSQ < 0.50, 1,695,815 genotyped or
imputed SNPs remained for meta-analyses.
To evaluate the population structure and identify potential genetic outliers, we performed
principal components analysis (PCA) using EIGENSTRAT, version 2.5 (23). We selected a
set of ~6,000 uncorrelated SNPs (closest distance between two SNPs > 200kb, MAF > 0.2,
r2 < 0.1, and call rate > 99%) shared among all 4,415 samples included in Stage 1 and the
HapMap Project using PLINK version 1.07 (24). Genotype data of these SNPs from the four
Stage 1 studies were pooled together with HapMap data (release 23a) to generate the first
ten principal components. Samples were removed from the final analysis if they were more
than 6σ away from the means of PC1 and PC2.
Associations of SNPs with CRC risk in each of the four studies included in Stage 1 were
assessed by assuming a log-additive effect of the allelic dosage of the SNPs. Odds ratios
(ORs) and 95% confidence intervals (CIs) were generated from logistic regression models,
adjusted for age, sex, and the first ten principal components. We coded 0, 1, or 2 copies of
the effect alleles as dosage for genotyped SNPs and used the expected number of copies of
the effect alleles as dosage score for imputed SNPs to account for imputation uncertainty
(25). The meta-analysis was performed using an inverse-variance method assuming fixed-
effects, with a Cochran's Q statistic to test for heterogeneity (26) and I2 statistic to quantify
heterogeneity (27) across studies. Summary statistics of genome-wide meta-analyses were
generated using the METAL program (28). Similar to Stage 1, we evaluated associations of
CRC risk with SNPs in each of the studies included in Stage 2 using logistic regression
models with adjustment for age and sex. Summary estimates in Stage 2, all studies
combined, and subgroups by populations (Chinese, Korean, and Japanese) and sex (male,
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female) were also obtained using a fixed-effects meta-analysis with METAL. SNPs showing
an association at P <5×10−8 in the combined analysis of all studies were considered
genome-wide significant. We conducted haplotype association analysis for two SNPs in
18q21.1 using SAS Genetics v9.3 with logistic regression models. The familial relative risk
(λ) to offspring of an affected individual due to a single locus is estimated using formula: λ
= (pr2 + q)/(pr + q)2, where p is the frequency of the risk allele, q = 1-p is the frequency of
the reference allele, and r is the per-allele relative risk (29). The proportion of the familial
relative risk explained by a locus, assuming a multiplicative interaction between markers in
the locus and other loci, is calculated as , where λo is the overall familial
relative risk which is assigned to be 2.2 for CRC estimated from a previous meta-analysis
(30). Assuming that the risks associated with each locus combine multiplicatively, the
combined contribution of the familial relative risks from multiple loci is equal to:
.
To visualize population substructure, we drew a PCA plot using data from the 4,415 Stage 1
samples and 270 subjects from HapMap based on the first two principal components using R
version 2.13.0 (http://www.r-project.org/). We also used R package to generate a forest plot
to display the association of rs7229639 with CRC risk across studies. We generated regional
association plots using the website-based software LocusZoom, version 1.1 (31). Haploview
version 4.2 (32) was used to infer linkage disequilibrium (LD) structure.
Results
A total of 19,179 samples are included in the current analysis (Table 1). Cases and controls
were reasonably well matched by age and sex in most of the participating studies. All
samples in Stage 1 showed a clear East Asian origin and none of them were more than 6σ
away from the means of PC1 and PC2 (Supplementary Figure 1). Cases and controls in
each of the four studies were in the same cluster compared with East Asians in HapMap.
After standard QC filter, a total of 1,695,815 SNPs were finally included in the association
analyses. Using Stage 1 data, we evaluated association of CRC risk with the 26 previously
reported SNPs. Of the 22 SNPs initially identified from GWAS conducted in European-
ancestry populations, rs6691170 and rs16892766 are monomorphic in East Asians. One
SNP, rs5934683 in Chromosome X, was excluded from analyses in this study. All other 19
SNPs showed an association with CRC risk in the same direction as reported initially
(Supplementary Table 1). Nine of 19 SNPs showed a statistically significant association
with CRC risk at P < 0.05. Of the four SNPs initially identified in East Asians, three
(rs647161, rs10774214 and rs2423279) were also significantly associated with CRC in our
Stage 1, and one (rs7758229) was not associated with CRC risk in these data. To identify
new genetic risk variants for CRC, we selected the 66 most promising SNPs for replication
in Stage 2 using the following criteria: 1) MAF > 0.05 in each of the four Stage 1 studies, 2)
RSQ > 0.70 in all four studies, 3) Pmeta < 5.5 × 10−5, 4) no heterogeneity (Pheterogeneity >
0.05 and I2 < 25%), 5) uncorrelated with SNPs in known CRC loci or with each other (r2 <
0.20), and 6) data available in all four Stage 1 studies. These 66 SNPs were not evaluated in
our previously published study (16).
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Of the 66 SNPs selected for Stage 2 replication, 59 SNPs were successfully genotyped in
3,612 cases and 3,523 controls from three studies (Guangzhou-2, Korea-NCC, and Korea-
Seoul) included in Stage 2 (Supplementary Table 2). Five SNPs (rs7923556, rs1539213,
rs7229639, rs7247381, and rs2143619) from five different regions (10q21.2, 14q21.3,
18q21.1, 19q12, and 20p12.2) showed an association with CRC risk at P-value < 0.05 in the
same direction as observed in Stage 1 (Supplementary Table 2). For these five SNPs, we
conducted in silico replication using data from three additional studies (KCPS-II, Japan-
BioBank, and SCH) with 2,899 cases and 3,867 controls. SNP rs7229639 was further
genotyped in Aichi-2 including 391 cases and 472 controls. Of all the 59 SNPs evaluated in
Stage 2, only rs7229639 was consistently associated with CRC risk across all seven studies,
showing strong evidence of replication, with P-value 3.39 × 10−8. Joint analysis of samples
in Stages 1 and 2 yielded per-allele OR (95% CI) 1.22 (1.15-1.29) and P-value 2.93 × 10−11
(Table 2), which is substantially lower than the genome-wide significance level of 5 × 10−8.
This association was consistent across all eleven studies in Stages 1 and 2 (Figure 1), with
little evidence of between-study heterogeneity (P for heterogeneity = 0.726, I2 = 0%).
Stratification analysis did not reveal any apparent heterogeneity across Chinese (OR = 1.20),
Korean (OR = 1.21), or Japanese (OR = 1.23) subjects (P for heterogeneity = 0.958), or
between men (OR = 1.28) and women (OR = 1.19) (P for heterogeneity = 0.268) for this
SNP (Table 2). Finally, using genotype data from four studies included in Stage 2, we found
that the risk of CRC was increased in a dose-response manner with the number of minor
allele (A) of rs7229639 (P for trend = 4.78 × 10−7), with ORs of 1.21 (95% CI: 1.10-1.34)
and 1.62 (95% CI: 1.26-2.08) for heterozygotes and homozygotes, respectively. These data
support an additive model rather than dominant (OR = 1.25, 95% CI: 1.14-1.38; P = 4.39 ×
10−6) or recessive model (OR= 1.52, 95% CI: 1.19-1.96; P = 9.95 × 10−4).
SNP rs7229639 is located in intron 3 of the SMAD7 gene at 18q21.1 (Supplementary
Figure 2), where three other SNPs (rs4939827, rs12953717, and rs4464148) have been
reported in previous GWAS conducted in European descendants to be associated with CRC
risk (5). In a fine-mapping analysis, rs58920878 was identified as a potential causal variant
in this region (33). SNP rs7229639 is not correlated with any of four previously reported
risk variants in this region in East Asians with r2 all under 0.05 (data from the 1000
Genomes Project). In European descendants, rs7229639 was weakly correlated with
r4939827 (r2 = 0.146) and not correlated with any of the four other SNPs (r2 < 0.07). Data
for these four previously reported SNPs were available in Stage 1, and three of the SNPs
showed statistically significant (rs4939827) or marginally significant (rs58920878 and
rs12953717) association with CRC risk in our Stage 1 (Table 3, Supplementary Table 1).
Of these previously reported risk variants, rs4939827 showed the strongest association with
CRC risk (OR =0.89, 95% CI, 0.80-0.98, P = 0.022) in Stage 1 of our study. Because
rs4939827 is in LD with both rs58920878 and rs12953717 in Asians (r2 > 0.8), we selected
rs4939827 for additional genotyping in Stage 2 (P = 0.008) (data not shown). A combined
analysis of samples from both Stages 1 and 2 yielded a per-allele OR (95% CI) of 0.90
(0.85-0.96) (P = 0.001) (data not shown).
Conditional analyses were performed to determine whether the observed association with
rs7229639 was independent of the other GWAS-identified SNPs in this region (Table 3).
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The association with rs7229639 remained statistically significant after adjusting for any of
these previously GWAS-identified SNPs individually or in combination. Interestingly,
adjusting for rs7229639 strengthened the associations of CRC risk with three (rs4939827,
rs58920878, and rs12953717) of the four SNPs reported from previous GWAS. Because
these three previously reported SNPs were strongly correlated, we selected rs4939827 for
further evaluation with rs7229639 in haplotype analysis. Haplotype analysis of rs7229639
and rs4939827 revealed two common haplotypes, A-C and G-T, to be statistically
significantly associated with CRC risk (Table 4). For haplotype A-C, the strength of
association with CRC (OR = 1.68, 95% CI, 1.37-2.07; P = 9.92 × 10−7) was greater than that
of either rs7229639 (OR = 1.22, 95% CI, 1.11-1.33; P = 3.43 × 10−5) or rs4939827 (OR =
0.90, 95% CI, 0.83-0.97; P = 0.007) alone. When dominant model was applied, three minor
haplotypes were associated with a 1.49-fold (95% CI, 1.29-1.72) increased risk of CRC (P =
5.01 × 10−8).
Discussion
In this two-stage GWAS of CRC including 8,675 cases and 10,504 controls from China,
Korea, Japan, and Singapore, we identified a new genetic variant (rs7229639) in the SMAD7
gene to be associated with CRC risk at genome-wide significance level. The association of
this SNP with CRC risk remained highly statistically significant after adjusting for all four
other risk variants reported previously in this region (5;33), providing evidence for the
presence of multiple genetic risk variants in the SMAD7 gene for CRC. SNP rs7229639
explained approximately 0.75% of the familial relative risk of CRC in East Asians, while
rs4939827, the risk variant identified originally in GWAS, explained about 0.3% of familial
relative risk. When haplotypes of these two variants are considered, these variants would
explain 1.9% of familial relative risk, approximately six-fold the 0.3% explained by the
original risk variant (rs4939827).
SNP rs7229639 (46,450,976 bp, NCBI Human Genome Build 37.3) is located in intron 3 of
the SMAD7 gene at chromosome 18q21.1. In this region, three other variants including
rs4939827 (46,453,463 bp), rs12953717 (46,453,929 bp), and rs4464148 (46,459,032 bp)
have been found to be associated with CRC risk through GWAS conducted in European-
ancestry populations (5). A subsequent fine-mapping through resequencing 17 kb region of
18q21.1 in a study conducted in European descendants identified a new variant, rs58920878
(46,449,565 bp) as a potential causal variant at this locus (33). SNP rs58920878 showed the
strongest association in that study and is correlated with rs4939827 (r2=0.533), rs12953717
(r2=0.927), and rs4464148 (r2=0.327) in European descendants. Although rs58920878 is
also in high LD with both rs4939827 (r2=0.830) and rs12953717 (r2=0.785) in East Asians,
it was only weakly associated with CRC risk in our study. The SNP (rs7229639) we
identified in this study showed the strongest association with CRC risk and is not correlated
with any of the four previously reported SNPs in both East Asian and European populations.
Therefore, as expected, adjustment for any or all of these four SNPs did not attenuate the
association of rs7229639 with CRC risk in the current study. Haplotype analyses further
confirmed the independent association of rs7229639 and rs4939827 with CRC risk in this
locus. It is possible that multiple causal variants may be present in this locus among East
Asians.
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The SMAD7 gene is a key member in TGF-β family signaling pathway which has been
shown to play a dual role in carcinogenesis, including tumor suppressor in early stage and
oncogene in advanced stage of cancers (34). Multiple genes in this pathway are known to be
involved in colorectal pathogenesis (35). SMAD7 gene encodes Smad family member 7
(Smad7), an inhibitory protein that functions as an antagonist of TGF-β signaling by
blocking phosphorylation of receptor-activated Smads or by competitive inhibition of
complex formation of receptor-activated Smads with the common-mediator Smad4 in the
cytoplasm and nucleus (36). Smad7 also serves as an important cross-talk mediator of the
TGF-β signaling pathway with other signaling pathways including Wnt signaling (36).
Expression of Smad7 was found in both normal colon mucosa and tumor cells (37), and
aberrant Smad7 expression may influence CRC progression (38). Recently, Smad7 was
shown to induce colorectal tumorigenicity through blocking TGF-beta-induced growth
inhibition and inhibiting apoptosis, and a certain proportion of human colorectal tumors may
become refractory to tumor suppressive actions of TGF-β that might lead to increased
tumorigenicity (39).
A recent study has showed that the previously-identified CRC risk variant rs4939827 may
be associated with CRC survival (40). This SNP was associated with certain characteristics
of CRC, including invasiveness of the cancer and RUNX3 methylation status (41). No
survival data, however, were collected in our study, and thus we could not evaluate these
SMAD7 variants, including the newly-identified risk variant rs7229639, with CRC survival
in our study.
In summary, this study identified a new CRC risk variant in the SMAD7 gene among East
Asians, which further highlights the significant role of this gene in the etiology of CRC. To
date, multiple CRC susceptibility loci have been identified by GWAS in TGFβ pathway
genes, including SMAD7, supporting an important role of this pathway in the pathogenesis
of CRC. Future studies are warranted to investigate these CRC susceptibility loci to identify
causal variants underlying the associations discovered in GWAS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What's new?
GWAS, conducted primarily in European ancestry populations, have identified common
genetic variants in approximately 20 loci associated with CRC risk. These variants
account for approximately 10% of familial risk of this common cancer. In a large GWAS
of CRC including approximately 19,000 individuals of East Asian ancestry, SNP
rs7229639 in the SMAD7 gene was found to be associated with CRC risk at genome-wide
significance level (P<5×10−8), independent of rs4939827 reported previously in this
region by an European GWAS. Findings from this study highlight the significant role of
this gene in the etiology of CRC and suggest that genetic risk variants may differ by
study populations.
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Figure 1. Association of rs7229639 with colorectal cancer risk by studies
Per-allele ORs are presented with the area of the box proportion to the inverse variance
weight of the estimate. Horizontal lines show 95% CIs.
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Table 2
Association of rs7229639 in the SMAD7 gene with colorectal cancer risk in East Asians
Sample size1 EAF2 Per-allele association Heterogeneity
Study Cases Controls Cases Controls OR (95% CI)3 P value P heterogeneity 4 I2 (%)
Stage 1 1,773 2,642 0.186 0.152 1.32 (1.17-1.50) 1.22×10−5 0.269 24
Stage 2 6,800 7,761 0.176 0.153 1.20 (1.13-1.28) 3.39×10−8 0.897 0
Overall 8,573 10,403 0.178 0.152 1.22 (1.15-1.29) 2.93×10−11 0.726 0
Chinese 3,670 4,204 0.170 0.145 1.20 (1.10-1.32) 6.65×10−5 0.958 0
Korean 2,525 2,889 0.215 0.185 1.21 (1.09-1.33) 1.85×10−4
Japanese 2,378 3,310 0.151 0.133 1.23 (1.10-1.38) 3.21×10−4
Male 3,542 4,338 0.190 0.156 1.28 (1.17-1.40) 2.88×10−8 0.268 19
Female 2,456 3,175 0.200 0.174 1.19 (1.07-1.32) 8.13×10−4
1
Data from Japan-BioBank and SCH studies were not included in the stratified analysis by sex.
2
Effect allele (A) frequency of cases and controls.
3OR was estimated based on the effect allele (A).
4
P for heterogeneity across studies was calculated using a Cochran's Q test
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Table 3
Evaluation of independent association of rs7229639 and other four risk variants in the SMAD7 gene in relation
to colorectal cancer risk
Test SNP (allele) Adjusted SNP(s) Cases/controls EAF1 OR (95% CI) P value
rs58920878 (C) None 1,773/2,642 0.734 0.92 (0.82-1.02) 0.097
rs7229639 (A) None 4,840/5,925 0.156 1.25 (1.16-1.34) 5.25×10−9
rs4939827 (C) None 4,840/5,925 0.727 0.90 (0.85-0.96) 8.87×10−4
rs12953717 (C) None 1,773/2,642 0.733 0.92 (0.83-1.01) 0.085
rs4464148 (C) None 1,773/2,642 0.059 0.97 (0.80-1.18) 0.770
rs7229639 (A) rs58920878 1,773/2,642 0.152 1.40 (1.23-1.60) 4.19×10−7
rs7229639 (A) rs4939827 4,840/5,925 0.156 1.30 (1.20-1.40) 1.87×10−11
rs7229639 (A) rs12953717 1,773/2,642 0.152 1.40 (1.23-1.60) 3.97×10−7
rs7229639 (A) rs4464148 1,773/2,642 0.152 1.32 (1.17-1.50) 1.25×10−5
rs7229639 (A) All four SNPs2 1,773/2,642 0.152 1.41 (1.23-1.61) 8.96×10−7
rs58920878 (C) rs7229639 1,773/2,642 0.734 0.84 (0.76-0.94) 0.002
rs4939827 (C) rs7229639 4,840/5,925 0.727 0.86 (0.81-0.92) 2.57×10−6
rs12953717 (C) rs7229639 1,773/2,642 0.733 0.85 (0.76-0.94) 0.002
rs4464148 (C) rs7229639 1,773/2,642 0.059 1.02 (0.84-1.24) 0.854
Abbreviations: EAF, effect allele frequency; OR, odds ratio; and CI, confidence interval.
1
Effect allele frequency of the tested SNP in controls.
2
rs58920878, rs4939827, rs12953717 and rs4464148.
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Table 4
Association of colorectal cancer risk with the haplotypes comprising rs7229639 and rs4939827
Frequency2
Haplotype1 Cases Controls OR (95% CI)3 P value
G-C 0.537 0.582 1.00 (Reference)
G-T 0.273 0.258 1.41 (1.18-1.67) 1.01×10−4
A-C 0.176 0.149 1.68 (1.37-2.07) 9.92×10−7
A-T 0.013 0.010 1.33 (0.54-3.26) 0.532
G-T/A-C/A-T 0.463 0.418 1.49 (1.29-1.72) 5.01×10−8
1
Haplotypes of rs7229639 and rs4939827.
2Analyses were based on 3,067 cases and 3,283 controls included in Stage 2.
3Adjusted for age, sex and study site.
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